International Conference on Fibromyalgia and Chronic Pain June 15-16, 2016 Philadelphia, Pennsylvania, USA

ConferenceSeries Ltd invites all the participants from all over the world to attend “International Conference on Fibromyalgia and chronic pain” which is going to be held during June 15-16, 2016. Conference includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions.

Fibromyalgia and chronic pain 2016 welcomes attendees, presenters, and exhibitors from all over the world to Philadelphia, USA. We are delighted to invite you all to attend and register for the “International Conference on Fibromyalgia and chronic pain”

Fibromyalgia (FM) is a medical condition characterised by chronic widespread pain and a heightened and painful response to pressure. Symptoms other than pain may occur, leading to the use of the term fibromyalgia syndrome (FMS).

The organizing committee is gearing up for an exciting and informative conference program including plenary lectures, symposia, workshops on a variety of topics, poster presentations and various programs for participants from all over the world. We invite you to join us at the Fibromyalgia and chronic pain, where you will be sure to have a meaningful experience with scholars from around the world. All members of the Fibromyalgia and chronic pain-2016 organizing committee look forward to meeting you in Philadelphia, USA.

Conference Opportunities

For Researchers and Faculty Members:

Speaker Presentations
Poster Display
Symposium hosting (4-5 member team)
Workshop organizing

For Universities, Associations & Societies:

Association Partnering
Collaboration proposals
Academic Partnering
Group Participation

For Students and Research Scholars:

Poster Competition (Winner will get Best Poster Award)
Young Researcher Forum (YRF Award to the best presenter)
Student Attendee
Group registrations

For Business Delegates:

Speaker Presentations
Symposium hosting
Book Launch event
Networking opportunities
Audience participation

For Product Manufacturers:

Exhibitor and Vendor boothsSponsorships opportunities
Product launch
Scientific Partnering
Marketing and Networking with clients

Fibromyalgia

Fibromyalgia (FM) is a medical condition characterised by chronic widespread pain and a heightened and painful response to pressure. Symptoms other than pain may occur, leading to the use of the term fibromyalgia syndrome (FMS). Other symptoms include feeling tired to a degree that normal activities are affected, sleep disturbance, and joint stiffness. Some people also report difficulty with swallowing, bowel and bladder abnormalities, numbness and tingling, and cognitive dysfunction. Fibromyalgia is frequently associated with psychiatric conditions such as depression and anxiety and stress-related disorders such as posttraumatic stress disorder. Not all people with fibromyalgia experience all associated symptoms.

Fibromyalgia is a central nervous system (CNS) illness, which includes the brain and spinal cord.  Nerve cell endings, or receptors, are at the front end of pain sensation

Reference: https://en.wikipedia.org/wiki/Fibromyalgia

Chronic pain

There are about 500 Million plus people suffer from chronic pain, defined as pain that lasts longer than six months. Chronic pain can be mild or excruciating, episodic or continuous, merely inconvenient or totally incapacitating. With chronic pain, signals of pain remain active in the nervous system for months or even years. This can take both a physical and emotional toll on a person.

The most common sources of pain stem from headaches, joint pain, pain from injury, and backaches. Other kinds of chronic pain include tendinitis, sinus pain, carpal tunnel syndrome, and pain affecting specific parts of the body, such as the shoulders, pelvis, and neck. Generalized muscle or nerve pain can also develop into a chronic condition.

Reference:http://www.webmd.com/pain-management/guide/understanding-pain-management-chronic-pain

Neuroscience

Its exact cause is unknown but is believed to involve psychological, genetic, neurobiological and environmental factors. There is evidence that environmental factors and certain genes increase the risk of developing fibromyalgia – these same genes are also associated with other functional somatic syndromes and major depressive disorder. The central symptom of fibromyalgia, namely widespread pain, appears to result from neuro-chemical imbalances including activation of inflammatory pathways in the brain which results in abnormalities in pain processing. The brains of people with fibromyalgia show functional and structural differences from those of people without fibromyalgia, but it is unclear whether the brain anomalies cause fibromyalgia symptoms or are the product of an unknown underlying common cause. Some research suggests that these brain anomalies may be the result of childhood stress, or prolonged or severe stress.

Fibromyalgia is recognized as a disorder by the US National Institutes of Health and the American College of Rheumatology. Fibromyalgia is described as a "central sensitization syndrome" caused by biological abnormalities in the nervous system which act to produce pain and cognitive impairments as well as psychological problems. Despite this, there is controversy as to the cause and nature of fibromyalgia, as well as how people affected are described by those in the medical community. Dr Frederick Wolfe, lead author of the 1990 paper that first defined the diagnostic guidelines for fibromyalgia, has stated he believes the causes of fibromyalgia "are controversial in a sense" and "there are many factors that produce these symptoms – some are psychological and some are physical and it does exist on a continuum."

Reference: https://en.wikipedia.org/wiki/Fibromyalgia

Patients affected by Fibromyalgia

Fibromyalgia is estimated to affect 2–8% of the population, with a female to male incidence ratio that is somewhere between 7:1 and 9:1. The term "fibromyalgia" derives from New Latin, fibro-, meaning "fibrous tissues", Greek myo-, "muscle", and Greek algos, "pain"; thus the term literally means "muscle and connective tissue pain".

Reference: https://en.wikipedia.org/wiki/Fibromyalgia

Management

As with many other medically unexplained syndromes, there is no universally accepted treatment or cure for fibromyalgia, and treatment typically consists of symptom management. Developments in the understanding of the pathophysiology of the disorder have led to improvements in treatment, which include prescription medication, behavioural intervention and exercise. Indeed, integrated treatment plans that incorporate medication, patient education, aerobic exercise and cognitive-behavioural therapy have been shown to be effective in alleviating pain and other fibromyalgia-related symptoms.

The Association of the Scientific Medical Societies in Germany, the European League against Rheumatism and the Canadian Pain Society currently publish guidelines for the diagnosis and management of FMS.

Reference: https://en.wikipedia.org/wiki/Fibromyalgia

Medications

Health Canada and the US Food and Drug Administration (FDA) have approved pregabalin and duloxetine, for the management of fibromyalgia. The FDA also approves milnacipran, but the European Medicines Agency refused marketing authority.

Reference: https://en.wikipedia.org/wiki/Fibromyalgia

Current market medicines

In 2007, Pfizers Lyrica became the first prescription medication approved for the treatment of fibromyalgia. Since then, two more drugs—Cymbalta and Savella—have joined its ranks, expanding the options to treat this painful chronic condition.

But because so much is still unknown about what causes fibromyalgia, there is no go-to treatment. In fact, typically only “35% to 40% of patients will respond well to any one of these three drugs,” says Daniel Clauw, MD, the director of the Chronic Pain and Fatigue Research Center at the University of Michigan, in Ann Arbor.

Reference: http://www.health.com/health/condition-article/0,,20326413,00.html

Research implementation

Research suggests that people with fibromyalgia may have extremely sensitive central nervous systems that perceive pain much more acutely than those with normal pain responses. There is also some evidence that people who suffer from fibromyalgia experience a range of sleep disturbances that may leave them more prone to pain. An even newer theory is that fibromyalgia may be related to compression of the cervical spinal cord, which can lead to sleep disruptions as well as widespread pain.

The three drugs currently approved for fibromyalgia are thought to ease the pain by acting on either the nerves or brain chemicals called neurotransmitters. Since these drugs do not have a high success rate, patients often use more than one or try several before finding one that works well with the least side effect

Reference: http://www.niams.nih.gov/health_info/fibromyalgia/

Why conference on FM and chronic pain?

The progression of fibromyalgia research has provided new knowledge about centralized pain that is already helping to open doors to better, more effective treatment for people with fibromyalgia. There have been assurances given to support the FM by NIH

Mission Statement:  The National Fibromyalgia & Chronic Pain Association unites patients, policy makers, and healthcare, medical and scientific communities to transform lives through visionary support, advocacy, research and education of fibromyalgia and chronic pain illnesses.

Vision Statement:  End chronic pain conditions from derailing lives by promoting early diagnosis, driving scientific research for a cure, and facilitating translational research for the THREE A's of Treatment for fibromyalgia and chronic pain:  Appropriate, Accessible, and Affordable.

Reference:http://www.fmcpaware.org/fibromyalgia-chronic-pain-life-magazine/140-magazine/1359-fibromyalgia-chronic-pain-life-magazine.html

Highlights of our Conference

Types of pain
Chronic pain
Causes of chronic pain
Effects and symptoms of FM and chronic pain
Fibromyalgia and cognition
Genetics and Conditions
Pathophysiology
Psychological and social effects
Medical or generalised disease processes
Pain Management

Scopes of our conference

The National Fibromyalgia & Chronic Pain Conference unites patients, policy makers, and healthcare, medical and scientific communities to transform lives through visionary support, advocacy, research and education of fibromyalgia and chronic pain illnesses.

To End chronic pain conditions from derailing lives by promoting early diagnosis, driving scientific research for a cure, and facilitating translational research for chronic pain's THREE A's of Treatment:  Appropriate, Accessible, and Affordable.

Top universities participation in Fibromyalgia and chronic pain research

University of Washington
University of cincinnati
University of Pittsburgh
University of Toronto
University of Missouri
Stony Brook Unive
Oregon Health Sciences University
California State University
University of Maranhão

Globally around 700 Universities on pain research

There are around 100 top Universities work towards Chronic pain research

Top hospitals participation in Fibromyalgia research

University Hospitals Geauga Medical Center
Massachusetts General Hospital
Weill Cornell Medical College\
Johns Hopkins University
Royal National Hospital for Rheumatic Diseases
Cleveland Clinic
University of Maryland Medical Center
Stanford Health Care-Stanford Hospital

Globally more than 20, 000 Hospitals working on Chronic Pain and pain management

Associations involved in fibromyalgia and chronic pain

National Fibromyalgia & Chronic Pain Association (NFMCPA)
American College of Rheumatology’s FM
National institute of health
National Institute of Arthritis and Musculoskeletal and Skin Diseases
National Fibromyalgia Association
National Fibromyalgia Partnership, Inc.
Arthritis Foundation
American Chronic Pain Association
Chronic Pain Association of Canada
American Academy of Pain Medicine
American Pain Society: APSInternational Association for the Study of Pain (IASP)
The British Pain Society
Canadian Pain Society
American Medical Associations
American Society for Pain management Nursing
Pain management associates Inc
Australian Pain Management Association
American Academy of Pain Management
Society for Pain practice Management
American Pain Society
American Society for Regional Anesthesia and Pain Medicine
American Academy of Pain Medicine
American Chronic Pain Association
American Society of Anesthesiologist
American Society of Anesthesiologists-Pain Medicine
American Society of Interventional Pain Physicians
Japan Fibromyalgia Support Association
International FM Community
Fibromyalgia & Chronic Fatigue Syndrome In Spain
The International Association for the Study of Pain
Fibromyalgia Association UK (FMA UK)
Fibromyalgia Association UK
UKFibromyalgia.com (UK)
Action for ME (UK)
ME Research UK
The ME Association (UK)
Deutsche Fibromalgie-Vereinigung (DFV) e.V.
Belgium ME/CFS Association
Switzerland:   C.E.D.O.F.F. (ME/CFS & FM)
ME/Chronic Fatigue Syndrome Association of Australia
ME/CFS Society (South Australia)
Associated New Zealand ME Society
CFS NETWORK JAPAN
Global Recognition Campaign for Multiple Chemical Sensitivities
Association FranÒ«aise du Syndrome de Fatigue Chronique et de Fibromyalgie-France
ME/CFS Foreningen (ME/CFS Association)-Denmark
Fatigatio e.V.: Bundesverband Chronisches Erschöpfungssyndrom (CFS/CFS/ME/ME)-German
Fibromalgia and CFS Support of York Region

Top List of companies’ investments on Fibromyalgia and Chronic pain

GlaxoSmithKline
Merck
CSC Pharmaceuticals
Crucell Products
Novartis Vaccines
Trp The Relief Products
Synthetic Biologics, Inc.
Cigna for Business Health Insurance Solutions
ME/CFS Australia (SA) Inc.
Eli Lilly & Co.
Pfizer etc.

Patient expenditure on FM-Case study

The 2012 Institute of Medicine Report about Pain in America reveals that more than 100 million Americans are in pain with an annual price tag more than 65 billion dollars.  The cost of fibromyalgia to both the individual and to society is extensive. A 2007 study found that 34% of fibromyalgia patients spend between $100- $1,000 per month above their insurance to see a healthcare professional. Prominent fibromyalgia researchers and specialists estimate the costs in the U.S. between $12-14 billion each year and accounts for a loss of 1-2% of the nation’s overall productivity.

Reference: http://www.fmcpaware.org/fibromyalgia/economic-burden.html

Market value peaks

The findings from the Pharmacor topic entitled Fibromyalgia reveal that, through 2020, an expanding drug-treated population and, to a lesser extent, the uptake of Forest Laboratories/Cypress Bioscience's Savella (milnacipran), Johnson & Johnson/Grünenthal’s Nucynta ER (tapentadol ER) and Pfizer’s controlled-release formulation of Lyrica (pregabalin CR), will help to offset sales lost to the generic erosion of Cymbalta and Lyrica. The fibromyalgia drug market will experience minimal growth over the next decade, increasing from nearly $1.6 billion in 2010 to less than $1.8 billion in 2020 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

In 2010, Cymbalta unseated Lyrica as the U.S. patient- and market-share leader. According to interviewed experts, Lyrica’s side effects, in particular its CNS side effects and weight gain side effect have significantly curbed the use of this agent in the fibromyalgia population.

The findings also reveal that the U.S. accounted for nearly 80 per cent of major-market fibromyalgia sales in 2010, and in 2020 the U.S. will account for two-thirds of worldwide sales for the indication. The majority of U.S. sales continue to be driven by the leading fibromyalgia-approved therapies—Cymbalta, Lyrica and Savella. In Europe and Japan, market expansion will be constrained by a dearth of approved therapies, lower diagnosis rates and less widespread recognition of the disorder.

Because fibromyalgia is a difficult condition to treat its symptoms vary widely from patient to patient and can include pain, depression, fatigue and sleep dysfunction, significant unmet need remains for effective treatments.

Resources:http://decisionresources.com/News-and-Events/Press-Releases/Fibromyalgia-092911

Fibromyalgia Market Value Forecast to 2018

There will be more drugs to be developed with the advancements made by the researcher’s forum with the extensive fund made by the NIH to the projects of Fibromyelgia and chronic pain.

Reference: http://www.sec.gov/Archives/edgar/data/1430306/000101376211002697/exh9902.pdf

http://www.transparencymarketresearch.com/fibromyalgia-therapeutics-market.html

Resources

https://en.wikipedia.org/wiki/Fibromyalgia
http://www.webmd.com/pain-management/guide/understanding-pain-management-chronic-pain
www.rheumatology.org -- American College of Rheumatology
www.niams.nih.gov -- National Institute of Arthritis and Musculoskeletal and Skin Diseases
www.arthritis.org -- Arthritis Foundation
www.fmaware.org -- National Fibromyalgia Foundation
www.fmnetnews.com -- Fibromyalgia Network
www.aapainmanage.org - American Academy of Pain Management
www.ampainsoc.org -- American Pain Society
www.medicalacupuncture.org -- American Association of Medical Acupuncture
www.asch.net -- American Society of Clinical Hypnosis
www.clinicaltrials.gov -- Find a clinical trial

"Recent trends, advancements and discoveries in treating Fibromyalgia and Chronic pain''

ConferenceSeries Ltd organizes conference series all around the world in 2016. We are glad to welcome you to the International Conference on Fibromyalgia and Chronic pain during June 16-17, 2016 at Philadelphia, USA. Fibromyalgia and Chronic pain conference will be organized around the theme “Recent trends, advancements and discoveries in treating Fibromyalgia and Chronic pain”.

Fibromyalgia and Chronic pain are the most common cause of serious disability and have a major but often unrecognized, impact on health and social services. There are 30 million people around the world living with a neurological condition which has a significant impact on their lives. Fibromyalgia is estimated to affect 2–8% of the population, with a female to male incidence ratio that is somewhere between 7:1 and 9:1.

Philadelphia is the 5th most populous city in the USA. There are about 80 Universities in and around Philadelphia, which are working in the field of Neurological disorders and Muscular disorders. Around 1000 neurologist, psychiatrist, neurosurgeons, orthopaedic, rheumatologists and physical therapists are working exclusively on Fibromyalgia and Chronic pain in USA.

The fibromyalgia drug market will experience minimal growth over the next decade, increasing from nearly $1.6 billion in 2010 to less than $1.8 billion in 2020 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

There will be more drugs to be developed with the advancements made by the researcher’s forum with the extensive fund made by the NIH to the projects of Fibromyalgia and chronic pain.

ConferenceSeries Ltd is an amalgamation of Open Access publications and worldwide international science conferences and events. Established in the year 2007 with the sole aim of making the information on Sciences and technology "Open Access", ConferenceSeries Ltd publishes 700 online open access scholarly journals in all aspects of Science, Engineering, Management and Technology journals. ConferenceSeries Ltd has been instrumental in taking the knowledge on Science & technology to the doorsteps of ordinary men and women. Research Scholars, Students, Libraries, Educational Institutions, Research centers and the industry are main stakeholders that benefitted greatly from this knowledge dissemination. ConferenceSeries Ltd also organizes 1000 International conferences annually across the globe, where knowledge transfer takes place through debates, round table discussions, poster presentations, workshops, symposia and exhibitions.